BioWorld

Feb. 14, 2005

New Model System Gives New Clues To Function Of BRCA2

NHGRI's Collins Stresses Need For New Privacy Protection Laws

Other News To Note

Amgen Confirms GDNF Halt In Parkinson's Development

Amgen Inc. will return to the drawing board with its drug for Parkinson's disease, GDNF, after further review of preclinical studies showed a risk of brain damage. (BioWorld Today) Read More

NIAID Studying Indevus' PRO 2000 Vaginal Gel To Slow HIV's Spread

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...